Depressive anxiety

Discovery Behavioral Health Launches First-of-its-kind AI Platform with Videra Health and Leading Research Hospital to Address the "One Year Recovery Gap"

Retrieved on: 
Thursday, September 28, 2023
Depressive anxiety, Learning, Depression, Learning health systems, Eating disorder, Harvard T.H. Chan School of Public Health, Social, Smartphone, Cone Health Women's Hospital, Speech, Brigham and Women's Hospital, Data collection, Social determinants of health, DBH, Practice, Doctor of Philosophy, Language, Harvard University, Behavior, Harvard Medical School, Medicine, Discovery, Public health, MD, Patient, Eating, Psychiatry, Hospital, LOS, Medical imaging, Pharmaceutical industry, Medical device, Nursing, Brigham

LOS ANGELES, Sept. 28, 2023 /PRNewswire/ -- Discovery Behavioral Health, Inc., an expanding network of 165 evidence-based mental health, substance use and eating disorder treatment centers, has entered into a clinical research agreement that will play an integral role in the launch of a new A.I.-driven platform called Discovery365. The platform tracks patient progress for 12 months after discharge from a behavioral treatment program, a period Discovery refers to as "the one-year recovery gap," when industry relapse rates are exceedingly high. The agreement joins Discovery Behavioral Health with experts from Brigham and Women's Hospital. Powered by Videra Health technology, the Discovery365 platform represents a paradigm shift in the industry.

Key Points: 
  • The agreement joins Discovery Behavioral Health with experts from Brigham and Women's Hospital .
  • Powered by Videra Health technology, the Discovery365 platform represents a paradigm shift in the industry.
  • We are working to make relapse the exception, not the rule of recovery," says John Peloquin, PhD, President and CEO of Discovery Behavioral Health.
  • "Infusing AI into the world of behavioral health through this trailblazing platform will significantly advance solutions for the betterment of patients everywhere.

Calyx Delivers Imaging Biomarkers to Advance Neuropsychiatric Treatment Development

Retrieved on: 
Tuesday, April 4, 2023
Psychiatry, Depressive anxiety, Partnership, Central nervous system, Drug development, Clinical data management, Schizophrenia, Biomarker, Magnetic resonance, CNS, MRI, Acquisition, MD, Biophysics, Parkinson's disease, Artificial intelligence, Regulation, Pharmaceutical industry, Medical imaging, Calyx

NOTTINGHAM, England and MORRISVILLE, N.C., April 4, 2023 /PRNewswire/ -- Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, today announced a strategic partnership with Ceretype Neuromedicine, Inc., whose novel functional MRI (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies.

Key Points: 
  • Calyx partners with top tech providers, offering novel imaging biomarkers to find treatments for unmet CNS medical needs
    The current lack of objective biomarkers presents a real challenge for researchers developing treatments for depression/anxiety, schizophrenia, and other neurological/psychiatric conditions such as Parkinson's Disease.
  • "A key component of Calyx's strategy is partnering with best-in-class technology providers to offer the innovative imaging biomarkers required to find new treatments for unmet medical needs," said Stephen M. Bravo, MD, Chief Medical Officer at Calyx.
  • "We're delighted to combine Ceretype's neuroscience, biophysics, and computing expertise with Calyx's 25 years of experience delivering reliable clinical trial imaging," said Emily Stern, CEO at Ceretype.
  • "Through this partnership, we will achieve our mission of improving psychiatric and neurologic patient outcomes through precision drug development and precision treatment."

Calyx Delivers Imaging Biomarkers to Advance Neuropsychiatric Treatment Development

Retrieved on: 
Tuesday, April 4, 2023
Psychiatry, Depressive anxiety, Partnership, Central nervous system, Drug development, Clinical data management, Schizophrenia, Biomarker, Magnetic resonance, CNS, MRI, Acquisition, MD, Biophysics, Parkinson's disease, Artificial intelligence, Regulation, Pharmaceutical industry, Calyx

NOTTINGHAM, England and MORRISVILLE, N.C., April 4, 2023 /PRNewswire/ -- Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, today announced a strategic partnership with Ceretype Neuromedicine, Inc., whose novel functional MRI (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies.

Key Points: 
  • The current lack of objective biomarkers presents a real challenge for researchers developing treatments for depression/anxiety, schizophrenia, and other neurological/psychiatric conditions such as Parkinson's Disease.
  • "A key component of Calyx's strategy is partnering with best-in-class technology providers to offer the innovative imaging biomarkers required to find new treatments for unmet medical needs," said Stephen M. Bravo, MD, Chief Medical Officer at Calyx.
  • "We're delighted to combine Ceretype's neuroscience, biophysics, and computing expertise with Calyx's 25 years of experience delivering reliable clinical trial imaging," said Emily Stern, CEO at Ceretype.
  • "Through this partnership, we will achieve our mission of improving psychiatric and neurologic patient outcomes through precision drug development and precision treatment."

Mobile Platform for Young People Debuts Critical Support Resource Library Centering Holiday Depression and Self-Harm Ideation

Retrieved on: 
Thursday, December 15, 2022
Trigger, Self-harm, Holiday, Adolescence, Family, Person, University of Texas Medical Branch, Violence, Suicidal ideation, Bullying, American Academy of Pediatrics, Trevor, Death, Peer Health Exchange, Housing, LGBTQ, CDC, BIPOC, American Academy, Ageing, Suicide, Trauma, Health minister, Risk, University, Human, Depressive anxiety, Computer, Mental health, Mobile phone, Toy

According to the Trevor Project’s 2022 study on LGBTQ+ youth self-harm and suicide ideation, 45% of LGBTQ+ youth seriously considered attempting suicide in the past year.

Key Points: 
  • According to the Trevor Project’s 2022 study on LGBTQ+ youth self-harm and suicide ideation, 45% of LGBTQ+ youth seriously considered attempting suicide in the past year.
  • LGBTQ+ youth who found their school to be LGBTQ-affirming reported lower rates of attempting suicide.
  • “We know that this time of year the general population experiences high rates of depression/anxiety and possible self-violent suicidal ideation, especially young people.
  • Together, we create education opportunities for peers to share the tools and resources young people need to make healthy decisions.

University of Tokyo and Sekisui House Launch Joint Research on Biodiversity and Health

Retrieved on: 
Tuesday, December 6, 2022
Sekisui House, University, Ecology and Society, Tree, University of Tokyo, Agriculture, Teriha Sekisui House Arena, Biodiversity, Research, Relaxation, Forest, Happiness, Garden, Mental health, University of the Ryukyus, Laboratory, COVID-19, Behavior, Ecology, Nature, Depressive anxiety, Ryukyu Islands, Loneliness, Health, Graduate school, Depression, Anxiety, Forestry, Pharmaceutical industry, Audit

In 2020, the Laboratory investigated how two means of interacting with nature -- the frequency of green space use and viewing greenery from the windows of homes -- affect the mental health of urban residents (self-esteem, life satisfaction, happiness, symptoms of depression/anxiety, and loneliness). The results of this research showed that not only people who frequently use green spaces, but also those who live in houses with green view reported better mental health (*2). This suggests that people can benefit from the psychological effects of nature from within their own homes even if they are not physically present in green spaces.

Key Points: 
  • TOKYO, Dec. 6, 2022 /PRNewswire/ --The University of Tokyo's Graduate School of Agricultural and Life Sciences (GSALS) and Sekisui House, Ltd. launched a joint research project on biodiversity and human health on December 1, 2022, to investigate the benefits that biodiversity and urban natural environments have on human health and well-being.
  • The Laboratory has been studying the relationship between nature and human health since 2016, and its research indicates that interactions with nature can lead to improved human health and well-being.
  • The Laboratory is conducting research to test five hypotheses regarding the relationship between human health and interactions with nature under the themes of mental health, physical health, cognitive functions, and community health.
  • This is, however, a long-term joint research project that will later also look at community health and other themes related to health.

University of Tokyo and Sekisui House Launch Joint Research on Biodiversity and Health

Retrieved on: 
Tuesday, December 6, 2022
Sekisui House, University, Ecology and Society, Tree, University of Tokyo, Agriculture, Teriha Sekisui House Arena, Biodiversity, Research, Relaxation, Forest, Happiness, Garden, Mental health, University of the Ryukyus, Laboratory, COVID-19, Behavior, Ecology, Nature, Depressive anxiety, Ryukyu Islands, Loneliness, Health, Graduate school, Depression, Anxiety, Forestry, Pharmaceutical industry, Audit

In 2020, the Laboratory investigated how two means of interacting with nature -- the frequency of green space use and viewing greenery from the windows of homes -- affect the mental health of urban residents (self-esteem, life satisfaction, happiness, symptoms of depression/anxiety, and loneliness). The results of this research showed that not only people who frequently use green spaces, but also those who live in houses with green view reported better mental health (*2). This suggests that people can benefit from the psychological effects of nature from within their own homes even if they are not physically present in green spaces.

Key Points: 
  • TOKYO, Dec. 6, 2022 /PRNewswire/ --The University of Tokyo's Graduate School of Agricultural and Life Sciences (GSALS) and Sekisui House, Ltd. launched a joint research project on biodiversity and human health on December 1, 2022, to investigate the benefits that biodiversity and urban natural environments have on human health and well-being.
  • The Laboratory has been studying the relationship between nature and human health since 2016, and its research indicates that interactions with nature can lead to improved human health and well-being.
  • The Laboratory is conducting research to test five hypotheses regarding the relationship between human health and interactions with nature under the themes of mental health, physical health, cognitive functions, and community health.
  • This is, however, a long-term joint research project that will later also look at community health and other themes related to health.

Moving Analytics joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

Retrieved on: 
Wednesday, November 23, 2022
Kaiser Permanente, Patient, Medicine, AHA, Partnership, FAHA, Innovation, Mayo Clinic, Collaborative innovation network, Depressive anxiety, Science, Network, Education, Exercise, Stanford University, Analytics, Research, American Heart Association, Policy, The Center, Hospital

IRVINE, Calif., Nov. 22, 2022 /PRNewswire-PRWeb/ -- Moving Analytics, leading provider of virtual cardiac rehabilitation and prevention, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

Key Points: 
  • Moving Analytics, leading provider of virtual cardiac rehabilitation and prevention, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network.
  • The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.
  • IRVINE, Calif., Nov. 22, 2022 /PRNewswire-PRWeb/ -- Moving Analytics, leading provider of virtual cardiac rehabilitation and prevention, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network.
  • The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

MySummerChallenge.com Helps Parents Keep Their Teens and Pre-Teens Healthy and Active All Summer

Retrieved on: 
Thursday, July 14, 2022
Television, Social media, Friends, Program, Multimedia, Passive, Depressive anxiety, Motion, County, Instagram, Parent, Summer Challenge Camp, DIY, County Fair, Cooking, TikTok, Toy, Friendly's

SEATTLE, July 14, 2022 /PRNewswire/ -- Mysummerchallenge.com announces its six-week teen and pre-teen summer series titled My Summer Challenge, filled with inspiration and creative ways to keep kids active and motivated all summer long.  The program launches this Saturday July 16th, 2022.

Key Points: 
  • SEATTLE, July 14, 2022 /PRNewswire/ -- Mysummerchallenge.com announces its six-week teen and pre-teen summer series titled My Summer Challenge, filled with inspiration and creative ways to keep kids active and motivated all summer long.
  • Parents are at their wits end this summer and do not know how to help their kids be kids again.
  • My Summer Challenge ( www.mysummerchallenge.com ) is launching this Saturday, July 16th and is a game-changer for parents, and their teen and pre-teenage kids.
  • My Summer Challenge is a six-week program designed help teens and pre-teens become more active in two areas: Mind and Motion.

Vivos Therapeutics’ SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea

Retrieved on: 
Tuesday, June 14, 2022
Apnea, Congress, Company, Snoring, Stroke, Dentist, Program, Securities Exchange Act of 1934, Drug Quality and Security Act, Apnea–hypopnea index, American Academy, CEO, Security (finance), CPAP, Mouth, Associated, U.S. Securities and Exchange Commission, Â, Heart failure, Depressive anxiety, VIP, Therapy, Manuscript, Patient, GLOBE, OSA, Risk, CARE, NASDAQ, Obstructive sleep apnea, Coronary artery disease, Mandibular advancement splint, Securities Act of 1933, Tissue, AHI, Pharmaceutical industry, Dentistry, Health insurance, Vivos

On June 6, 2022, Dr. Seth Heckman, Vivos Medical Advisory Board member, led a presentation, titled, Non-Surgical Maxillary Expansion Using A Novel Oral Appliance System.

Key Points: 
  • On June 6, 2022, Dr. Seth Heckman, Vivos Medical Advisory Board member, led a presentation, titled, Non-Surgical Maxillary Expansion Using A Novel Oral Appliance System.
  • The study participants experienced statistically significant increases in both transpalatal widths (4.5 percent) and airway volumes (11.1 percent).
  • Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for Home Sleep Testing in adults and children.
  • The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method.

US FDA accepts New Drug Application filed by Avillion for AstraZeneca's PT027 for the as-needed treatment or prevention of symptoms in asthma patients

Retrieved on: 
Tuesday, May 31, 2022
Inflammation, Risk, Budesonide, Medicine, Kidney, Food, US Foods, Cataract, International Conference on Nuclear Disarmament, Oslo, 2008, Asthma, International, Global Initiative for Asthma, Salbutamol, New Drug Application, Patient, File, Health, Treatment, American Thoracic Society, The New England Journal of Medicine, Pneumonia, SABA, Global Initiative, Thakeham, FDA, Bronchoconstriction, Partnership, ICS, Time, ATS, Conference, Safety, Wheeze, NDA, Drug development, Breathe Me, Depressive anxiety, OCS, MD, Cardiovascular disease, AstraZeneca, Pharmaceutical industry

The proposed indication is for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbations in patients with asthma 4 years of age and older.

Key Points: 
  • The proposed indication is for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbations in patients with asthma 4 years of age and older.
  • Under the terms of the agreement, Avillion funded, sponsored, and executed a multicentre, global clinical trial programme for PT027 comprising four studies involving more than 4,000 patients.
  • Following the successful approval of PT027, AstraZeneca has the option, upon certain financial payments, to commercialise the medicine in the US.
  • The NDA submission is based on data from studies conducted by AstraZeneca and Avillion to assess the safety and efficacy of PT027.